Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557970 · ClinicalTrials.gov registry record · Phase 2
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03557970 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 3 participants.
The verdict
NCT03557970, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well edicotinib (JNJ-40346527) works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. JNJ-40346527 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Pharmacokinetic Study
- DRUG Edicotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2020-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557970
The ClinicalTrials.gov registry entry for NCT03557970 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacokinetic Study is the first listed.
NCT03557970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03557970 about?
NCT03557970 is a clinical study titled "JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia". This phase II trial studies how well edicotinib (JNJ-40346527) works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. JNJ-40346527 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03557970?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-10-05. Estimated completion is 2020-09-28.
What interventions are being tested in trial NCT03557970?
The interventions under investigation include: Pharmacokinetic Study (OTHER), Edicotinib (DRUG).
Who is sponsoring clinical trial NCT03557970?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.